Improving CAR Treg therapy for Alzheimer's disease
Official title: Enhanced persistence of CAR Tregs in the CNS for Alzheimer’s disease therapy
Funded at Dartmouth College · NIH-11017414 · Data updated 2026-11-12
This study is looking at a new way to help treat Alzheimer's disease by using special immune cells that can reduce inflammation in the brain, and it aims to see if this approach can help slow down the disease for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $704,198 |
| NIH project number | 1R61AG090275-01 |
| Project ID | NIH-11017414 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those experiencing significant cognitive decline.
✕Less likely to help
Patients with early-stage Alzheimer's or those without significant neuroinflammation may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of CAR T regulatory cells (Tregs) in treating Alzheimer's disease by improving their persistence in the central nervous system (CNS). The approach involves using genetically modified Tregs that can target and reduce inflammation associated with amyloid-beta accumulation, a key factor in Alzheimer's progression. By investigating the mechanisms of Treg function and their interaction with neuroinflammation, the research aims to develop a novel therapeutic strategy that could potentially slow down or halt disease progression. Patients may be involved in trials assessing the safety and efficacy of this innovative treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly slows the progression of Alzheimer's disease and improves cognitive function.
How similar studies have gone: Previous research has shown promise in using Tregs for neuroinflammatory conditions, suggesting potential success for this novel approach in Alzheimer's disease.
Where this research is happening
-
Dartmouth College
Hanover, United States Active
Researchers
- Principal investigator: Sentman, Charles L. — Dartmouth College
- Study coordinator: Sentman, Charles L.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.